• Birinapant is a second generation bivalent SMAC mimetic in development for cancer and Hepatitis B.
  • SHAPE SHAPE is a novel HDAC inhibitor being developed for topical use in early-stage CTCL.

Pipeline

Oncology Pre-CLINICAL Phase 1 Phase 2
Myelodysplastic Syndromes (MDS) Birinapant
Cutaneous T-Cell Lymphoma (CTCL) SHAPE
Colorectal Cancer (CRC) Birinapant
Ovarian Cancer Birinapant
Infectious Disease
Hepatitis B Birinapant